Sarcopenic Obesity: Estimation of Prevalence and Identification of Clinical and Biological Determinants in a Cohort of Adult Obese Patients and Longitudinal Follow-up
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Mar 11, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called sarcopenic obesity (SO), which occurs when a person has both excess body fat and a loss of muscle mass. The research aims to find out how common sarcopenic obesity is among adults aged 18 to 70 who are considered obese, which means they have a body mass index (BMI) over 30. The goal is to identify the factors that contribute to muscle loss in people with obesity, especially since this condition is often overlooked in younger adults compared to older individuals.
To participate in this study, you need to be between 18 and 70 years old, be a man or woman, and have a BMI over 30. You also need to be receiving nutritional care to help manage your health. Unfortunately, individuals with certain severe health issues, such as cancer or serious muscle diseases, cannot take part in the trial. If you join, you can expect to be followed over a period of 5 to 10 years to see how your body composition and muscle function change. Additionally, there will be a shorter follow-up for those who have had weight loss surgery to understand how quick weight loss affects muscle health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: 18-70
- • Sex: men and women
- • Clinical nutrition patient receiving a metabolic assessment to optimise clinical and paraclinical management
- • Patient meeting obesity criteria defined by BMI \> 30 kg/m².
- • Patient of legal age who has given free, informed and signed consent
- • Patient covered by social security
- Non-inclusion criteria :
- • Patients with cancer or severe chronic disease (renal failure, respiratory failure, liver failure)
- • Patients with neuromuscular disease
- • Patient with total walking disability
- • Patients who are minors
- • Patient refusing to take part in the study
- • Pregnant or breast-feeding women
- • Under guardianship, curatorship, deprived of liberty or under court protection
- • Patient who has taken part in the OBESAR study
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Patients applied
Trial Officials
Yves BOIRIE
Principal Investigator
University Hospital, Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported